Why This Regeneron Approval ' Could Not Come Soon Enough '

Shares of REGN stock jumped Monday after the Food and Drug Administration approved Regeneron Pharmaceuticals' (REGN) high-dose Eylea following a delay this summer. Late Friday, the FDA signed off on an 8-milligram dose of Eylea to treat three eye diseases: wet age-related macular degeneration,…#eylea #fda #regeneron #pipersandler #christopherraymond #novartis #vabysmo #rbccapitalmarkets #brianabrahams #standardeylea
Source: Reuters: Health - Category: Consumer Health News Source Type: news